H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Leap Therapeutics Inc (LPTX) today and set a price target of $12.50. The company’s shares closed yesterday at $3.95, close to its 52-week low of $3.75.
Ramakanth commented:
“We maintain our Buy rating of Leap Therapeutics and our 12-month price target of $12.50 per diluted share. We derive our price target based on a risk-adjusted NPV (rNPV) analysis of projected DKN-01 and TRX518 revenues through 2030 assuming a 12% discount rate and 2% terminal growth rate. We derive an rNPV of $638M for the products and add in cash and cash equivalents of $23.2M to arrive at a 12-month price target of $12.47 per diluted share, which we round to $12.50. (1) clinical; (2) commercial; (3) partnership; (4) financial; and (5) legal and intellectual property.”
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.4% and a 32.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Tyme Technologies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Leap Therapeutics Inc with a $12.50 average price target.
See today’s analyst top recommended stocks >>
Based on Leap Therapeutics Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $6.63 million. In comparison, last year the company had a GAAP net loss of $6.82 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company. It invests in great science and targeted research will rapidly translate molecules into high impact therapeutics. The firm’s pipeline is built upon identifying and developing translational-stage molecules in the areas of cell signaling and immuno-oncology.
